1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Receptos radiant on top-line data for Gilenya rival

 
• By Mandy Jackson

Receptos jumped 32% in after-hours trading on 9 June after the San Diego-based company said its sphingosine-1-phosphate receptor 1 (S1P1) agonist RPC1063 met the primary endpoint of reduction in MRI brain lesion activity for multiple sclerosis patients enrolled in the Phase II portion of the Phase II/III RADIANCE clinical trial.

Receptos jumped 32% in after-hours trading on 9 June after the San Diego-based company said its sphingosine-1-phosphate receptor 1 (S1P1) agonist RPC1063 met the primary endpoint of reduction in MRI brain lesion activity for multiple sclerosis patients enrolled in the Phase II portion of the Phase II/III RADIANCE clinical trial.

Executives revealed few details, but indicated that the results so far "exceeded expectations" and showed a differentiated profile relative to approved and investigational MS drugs in the same class....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

More from Therapy Areas

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.